{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:54:14Z","timestamp":1790268854323,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-104-100"],"award-info":[{"award-number":["DMR-104-100"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["104-2325-B-039-004"],"award-info":[{"award-number":["104-2325-B-039-004"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006737","name":"National Center of Excellence for Clinical Trial and Research","doi-asserted-by":"publisher","award":["MOHW105-TDU-B-212133019"],"award-info":[{"award-number":["MOHW105-TDU-B-212133019"]}],"id":[{"id":"10.13039\/501100006737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006280","name":"Ministerio de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.biopsych.2017.12.006","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T12:35:39Z","timestamp":1514291739000},"page":"422-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1016","volume":"84","author":[{"given":"Chieh-Hsin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Cune","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yuan","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2017.12.006_bib1","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/pds.4244","article-title":"Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups","volume":"26","author":"Lao","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.biopsych.2017.12.006_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamapsychiatry.2015.2966","article-title":"The role of clozapine in treatment-resistant schizophrenia","volume":"73","author":"Kane","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/archpsyc.58.1.24","article-title":"Stability and course of neuropsychological deficits in schizophrenia","volume":"58","author":"Heaton","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2013.02.009","article-title":"Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia","volume":"146","author":"Lin","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs\u00a0in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2017.12.006_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YCO.0000000000000159","article-title":"Schizophrenia: When clozapine fails","volume":"28","author":"Miyamoto","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib10","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2017.12.006_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2011.08.005","article-title":"Clozapine resistance: Augmentation strategies","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2017.12.006_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0034-1383656","article-title":"Clozapine augmented with glutamate modulators in refractory schizophrenia: A review and metaanalysis","volume":"47","author":"Veerman","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1017\/S1461145708009085","article-title":"Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: Association with N-methyl-D-aspartic acid receptor up-regulation","volume":"12","author":"Gray","year":"2009","journal-title":"Int J Neuropsychomharmacol"},{"key":"10.1016\/j.biopsych.2017.12.006_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lfs.2008.05.014","article-title":"Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area","volume":"83","author":"Schwieler","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2017.12.006_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.mp.4001552","article-title":"Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action","volume":"10","author":"Javitt","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.pbb.2011.03.023","article-title":"Glutamate signaling in the pathophysiology and therapy of schizophrenia","volume":"100","author":"Lin","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2017.12.006_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1517\/14728214.10.4.827","article-title":"Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia","volume":"10","author":"Heresco-Levy","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.biopsych.2017.12.006_bib18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/schbul\/sbs076","article-title":"NMDA receptor and schizophrenia: A brief history","volume":"38","author":"Coyle","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2017.12.006_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002804","article-title":"Translating glutamate: From pathophysiology to treatment","volume":"3","author":"Javitt","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.biopsych.2017.12.006_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpba.2015.03.024","article-title":"D-aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia","volume":"116","author":"Errico","year":"2015","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.biopsych.2017.12.006_bib22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14728222.2014.934225","article-title":"Targeting of NMDA receptors in new treatments for schizophrenia","volume":"18","author":"Hashimoto","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.biopsych.2017.12.006_bib23","doi-asserted-by":"crossref","first-page":"18631","DOI":"10.1016\/S0021-9258(19)37007-3","article-title":"Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase","volume":"267","author":"Fukui","year":"1992","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.biopsych.2017.12.006_bib24","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1021\/bi963023s","article-title":"Limited proteolysis and X-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of D-amino acids catalyzed by mammalian D-amino acid oxidase","volume":"36","author":"Vanoni","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1073\/pnas.1114639109","article-title":"D-amino acid oxidase controls motoneuron degeneration through D-serine","volume":"109","author":"Sasabe","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2017.12.006_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2008.02.002","article-title":"Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia","volume":"101","author":"Madeira","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1874104501004020003","article-title":"The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors","volume":"4","author":"Smith","year":"2010","journal-title":"Open Med Chem J"},{"key":"10.1016\/j.biopsych.2017.12.006_bib28","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/S0021-9258(19)83631-1","article-title":"Thermodynamic control of D-amino acid oxidase by benzoate binding","volume":"260","author":"Van den Berghe-Snorek","year":"1985","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.biopsych.2017.12.006_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130398","article-title":"Cinnamon and its metabolite sodium benzoate attenuate the activation of p21rac and protect memory and learning in an animal model of Alzheimer's disease","volume":"10","author":"Modi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2017.12.006_bib30","unstructured":"Joint FAO\/WHO Expert Committee on Food Additives (1973): 21 CFR \u00a7184.1733-sodium benzoate. Available at: https:\/\/www.gpo.gov\/fdsys\/pkg\/CFR-2004-title21-vol3\/pdf\/CFR-2004-title21-vol3-sec184-1733.pdf. Accessed September 12, 2013."},{"key":"10.1016\/j.biopsych.2017.12.006_bib31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1203\/00006450-198804000-00006","article-title":"Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse","volume":"23","author":"Batshaw","year":"1988","journal-title":"Pediatr Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-016-0513-0","article-title":"Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: A multicentre retrospective study","volume":"11","author":"Husson","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.biopsych.2017.12.006_bib33","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamapsychiatry.2013.2159","article-title":"Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor","volume":"70","author":"Lane","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1196\/annals.1418.005","article-title":"Glutamate and neurotrophic factors in neuronal plasticity and disease","volume":"1144","author":"Mattson","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2017.12.006_bib35","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/jnr.21325","article-title":"Neuroinflammation and regulation of glial glutamate uptake in neurological disorders","volume":"85","author":"Tilleux","year":"2007","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJM199403033300907","article-title":"Excitatory amino acids as a final common pathway for neurologic disorders","volume":"330","author":"Lipton","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2017.12.006_bib37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1474-4422(08)70165-0","article-title":"NMDA receptors in clinical neurology: Excitatory times ahead","volume":"7","author":"Kalia","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.biopsych.2017.12.006_bib38","series-title":"Structured Clinical Interview for DSM-IV","year":"1994"},{"key":"10.1016\/j.biopsych.2017.12.006_bib39","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th ed","year":"1994"},{"key":"10.1016\/j.biopsych.2017.12.006_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2017.12.006_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","article-title":"The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundations","volume":"7","author":"Andreasen","year":"1989","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.biopsych.2017.12.006_bib42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2017.12.006_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A\u00a0rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A\u00a0placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2466\/pr0.1966.19.1.3","article-title":"The intraclass correlation coefficient as a measure of reliability","volume":"19","author":"Bartko","year":"1966","journal-title":"Psychol Rep"},{"key":"10.1016\/j.biopsych.2017.12.006_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.biopsych.2017.12.006_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.biopsych.2017.12.006_bib49","series-title":"Essentials of Behavioral Research: Methods and Data Analysis, 2nd ed","author":"Rosenthal","year":"1991"},{"key":"10.1016\/j.biopsych.2017.12.006_bib50","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1517\/14656566.2014.956082","article-title":"Augmentation strategies in partial responder and\/or treatment-resistant schizophrenia patients treated with clozapine","volume":"15","author":"Muscatello","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.biopsych.2017.12.006_bib51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/15622975.2015.1117654","article-title":"Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial","volume":"18","author":"Lin","year":"2017","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia","volume":"60","author":"Lane","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib53","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"D-serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.jcp.0000165740.22377.6d","article-title":"Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results","volume":"25","author":"Diaz","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2017.12.006_bib55","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo-controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib56","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A\u00a0placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib57","doi-asserted-by":"crossref","first-page":"14482","DOI":"10.1073\/pnas.95.24.14482","article-title":"Prolonged activation of the N-methyl-D-aspartate receptor-Ca2+ transduction pathway causes spontaneous recurrent epileptiform discharges in hippocampal neurons in culture","volume":"95","author":"DeLorenzo","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2017.12.006_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-1781(99)00042-6","article-title":"Choosing negative symptom instruments: Issues of representation and redundancy","volume":"87","author":"Welham","year":"1999","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib59","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/YCO.0b013e328314e144","article-title":"The new approach: Psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia","volume":"21","author":"Juckel","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib60","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.schres.2008.04.037","article-title":"Validation of the Personal and Social Performance (PSP) scale in a German sample of acutely ill patients with schizophrenia","volume":"104","author":"Juckel","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib61","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4088\/JCP.v60n0108","article-title":"Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics","volume":"60","author":"Lane","year":"1999","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.07.001","article-title":"New therapeutic approaches for treatment-resistant schizophrenia: A look to the future","volume":"58","author":"Miyamoto","year":"2014","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic - A meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2017.12.006_bib65","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00004714-200110000-00005","article-title":"A\u00a0placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia","volume":"21","author":"Goff","year":"2001","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2017.12.006_bib66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.npp.1301444","article-title":"A\u00a0placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia","volume":"33","author":"Goff","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2017.12.006_bib67","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine","volume":"70","author":"de Lucena","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco-Levy","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1017\/neu.2015.1","article-title":"Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine","volume":"27","author":"Matsuura","year":"2015","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.biopsych.2017.12.006_bib71","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3109\/08923973.2011.561861","article-title":"Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate","volume":"33","author":"Pahan","year":"2011","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.biopsych.2017.12.006_bib72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11064-016-1838-8","article-title":"Modulating NMDA receptor function with D-amino acid oxidase inhibitors: Understanding functional activity in PCP-treated mouse model","volume":"41","author":"Sershen","year":"2016","journal-title":"Neurochem Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib73","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/j.1476-5381.2011.01680.x","article-title":"D-Amino acid oxidase-mediated increase in spinal hydrogen peroxide is mainly responsible for formalin-induced tonic pain","volume":"165","author":"Lu","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2017.12.006_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/hum.1998.9.2-185","article-title":"Induction of cytotoxic oxidative stress by D-alanine in brain tumor cells expressing Rhodotorula gracilis D-amino acid oxidase: A cancer gene therapy strategy","volume":"9","author":"Stegman","year":"1998","journal-title":"Human Gene Ther"},{"key":"10.1016\/j.biopsych.2017.12.006_bib75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00702-017-1782-z","article-title":"A\u00a0systematic meta-analysis of the association of neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)\/G72 polymorphisms with schizophrenia","volume":"125","author":"Jagannath","year":"2018","journal-title":"J\u00a0Neural Transm (Vienna)"},{"key":"10.1016\/j.biopsych.2017.12.006_bib76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.12688\/wellcomeopenres.12171.1","article-title":"Haplotype-based association analysis of general cognitive ability in Generation Scotland, the English Longitudinal Study of Ageing, and UK Biobank","volume":"2","author":"Howard","year":"2017","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.biopsych.2017.12.006_bib77","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mp.2009.99","article-title":"The neurobiology of D-amino acid oxidase and its involvement in schizophrenia","volume":"15","author":"Verrall","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib78","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/mp.2013.80","article-title":"Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals","volume":"19","author":"Lin","year":"2014","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib79","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1017\/neu.2016.34","article-title":"Increased serum G72 protein levels in patients with schizophrenia: A potential candidate biomarker","volume":"29","author":"Akyol","year":"2017","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.biopsych.2017.12.006_bib80","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00018-016-2165-6","article-title":"G72 primate-specific gene: A still enigmatic element in psychiatric disorders","volume":"73","author":"Sacchi","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.biopsych.2017.12.006_bib81","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biopsych.2013.03.018","article-title":"Meta-analysis of oxidative stress in schizophrenia","volume":"74","author":"Flatow","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2017.12.006_bib82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/1735-5362.213984","article-title":"The protective effect of sodium benzoate on aluminum toxicity in PC12 cell line","volume":"12","author":"Arabsolghar","year":"2017","journal-title":"Res Pharm Sci"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322317322977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322317322977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:01:19Z","timestamp":1762099279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322317322977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0006322317322977"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2017.12.006","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2017.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}